欢迎访问《现代生物医学进展》编辑部！

目的：研究ASPP蛋白在非小细胞肺癌中的表达情况，探讨其表达与患者预后之间的关系。方法：选取于我院就诊的86 例非小细胞肺癌患者，病理学诊断癌症分型及分期，对所有患者进行随访，并用免疫组化法检测患者组织切片中ASPP2、iASPP 和p53 的表达，SPSS软件分析ASPP2、iASPP 表达水平与患者预后的关系。结果：NSCLCⅢ期的患者中ASPP2 阳性表达的中位生存期大于阴性患者，iASPP阴性表达患者的中位生存期大于阳性患者（P<0.05）；p53 野生型Ⅲ期患者ASPP2 阳性表达者的中位生存期显著大于阴性表达患者，Ⅰ、Ⅲ期iASPP 阴性表达患者的中位生存期显著大于阳性表达患者义（P<0.05）。p53 突变型患者Ⅲ期i- ASPP阴性表达患者的中位生存期显著大于阳性表达患者（P<0.05）。ASPP2 和iASPP 蛋白的表达水平和治疗方式均为影响患者预后的因素（P<0.05）。结论：ASPP2 的阳性表达和iASPP的阴性表达是NSCLC 的保护因素，可在一定程度上预测患者的生存期。

英文摘要:

Objective:To study the expression of ASPP in non-small cell lung cancer (NSCLC), and analysis the relationship between expression of ASPP and prognosis.Methods:Eighty-six NSCLC patients were recruited in this study; pathological detection was conducted to test the pathological classification and stage; immunohistochemical was used to detect the expression levels of ASPP2, iASPP and p53 in the pathological section and then SPSS 17.0 was used to analyze the relationship between the levels of ASPP2, iASPP and prognosis of NSCLC.Results:The median survival time of NSCLC patients in stage Ⅲ was longer in the ASPP2 positive group than the negative group, and longer in iASPP negative group than in the positive group (P<0.05). In p53 wild type, the median survival time of NSCLC patients in stage Ⅲ was longer in the ASPP2 positive group than the negative group, and longer in iASPP negative group than positive group in stageⅠ and Ⅲ (P<0.05). In p53 mutant type, median survival time of NSCLC patients in stage Ⅲ was longer in the iASPP negative group than in the positive group (P<0.05). The expression of ASPP2, iASPP and treatment method are all influencing factor to the prognosis of NSCLC (P<0.05).Conclusion:The positive expression of ASPP2 and the negative expression of iASPP are all protective factors to NSCLC patients, and can be used to predict the survival time in some extent.

查看全文查看/发表评论下载PDF阅读器

关闭